Accuray Inc., a Sunnyvale, Calif.-based developer of a robotic radio-surgery system, priced 16 million common shares at $18 per share, for an IPO take of approximately $288 million. It originally filed to price 13.3 million shares at between $14-$16 per share, but later raised the price range to $17-$18 per share. It will trade on […]
National CineMedia Inc., a Centennial, Colo.-based distributor of in-theater advertising, priced 38 million common shares at $21 per share ($18-$20 range), for an IPO take of approximately $798 million. It will trade on the Nasdaq under ticker symbol NCMI, while Credit Suisse, JPMorgan, Lehman Brothers and Morgan Stanley served as co-lead underwriters. Shareholders include Madison […]
Accuray Inc., a Sunnyvale, Calif.-based developer of a robotic radio-surgery system, has increased its proposed IPO price from $14-$16 per share to $17-$18 per share. It will plans to offer 13.33 million common shares and trade on the Nasdaq under ticker symbol ARAY. JPMorgan and UBS are serving as co-lead underwriters. Shareholders include BVI International […]
Switch and Data, a Tampa, Fla.-based provider of Internet exchange infrastructure, priced 11.67 million common shares at $17 per share ($14-$16 range), for an IPO take of approximately $198.39 million. It will trade on the Nasdaq under ticker symbol SDXC, while Deutsche Banc Securities and Jefferies & Co. served as co-lead underwriters. Switch and Data […]
Mellanox Technologies Inc., a Santa Clara, Calif.-based provider of interconnect solutions for servers, storage and infrastructure equipment, priced 6 million common shares at $17 per share, for an IPO take of approximately $102 million. It originally planned to price at between $12-$14 per share, and later upped its range to $14-$16 per share. It will […]
NeurogesX Inc., a San Carlos, Calif.-based developer of pain management therapies, has filed for a $69 million IPO. It plans to trade on the Nasdaq under ticker symbol NGSX, with Morgan Stanley serving as lead underwriter. The company has raised around $95 million in total VC funding since its 1998 inception, from firms like Arch […]
Biodel Inc., a Danbury, Conn.-based drug improvement company focused on endocrine disorders like diabetes and osteoporosis, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol BIOD, with Banc of America Securities serving as lead underwriter. The company raised $21 million in Series B funding last summer, and […]
Optimer Pharmaceuticals Inc., a San Diego-based developer of anti-infective products, has decreased its proposed IPO price range from $12-$14 per share to $8-$9 per share. It still plans to offer 5.25 million common shares, and trade on the Nasdaq under ticker symbol OPTR. Piper Jaffray and Jefferies & Co. are serving as co-lead underwriters. It […]
Vantage Oncology Inc., an El Segundo, Calif.-based owner and operator of radiation oncology centers, has raised $22.5 million in Series D funding, according to a regulatory filing. Camden Partners was joined by return backers New Enterprise Associates, Conning Capital Partners, Versant Ventures and Salix Ventures. www.vantageoncology.com
BIND Biosciences Inc., a Waltham, Mass.-based biotech startup, has raised $2.5 million in Series A funding, according to a regulatory filing. Backers include Flagship Ventures and Polaris Venture Partners, while the company is run by former TransForm Pharmaceuticals president Paul Goldenheim.